Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Antisense Therapeutics Limited	
ABN 41 095 060 745	

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Garner
Date of appointment	08/05/2023

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	**Number & class of Securities** Nil

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Employment Contract
Nature of interest	6,690,000* unlisted options to be granted subject to shareholder approval at the Company's next shareholder meeting in accordance with the ASX Listing Rules. These options will be granted in accordance with the terms of the Company's Employee Share Option Plan (ESOP) and will include the following terms and conditions: Issue price: Nil. Exercise Price: five-day VWAP of the Company's shares traded on the ASX immediately prior to the date of appointment announcement (8 May 2023). Expiry Date: 5 years from issue date. Vesting conditions: Vested over 48 months from appointment announcement date.
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	6,690,000* unlisted options

*Issuance of these securities is subject to receipt of shareholder approval at the Company's next shareholder meeting.